Novartis Brings “Disruptive Innovation” To Clinical Trials
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Having reinvigorated its model for early R&D, the company is looking to re-envision the clinical trial process, with initiatives aimed at improving patient selection based on molecular information, clinical trial recruitment and monitoring. A partnership with Walgreens aims to move trials out of tertiary care centers and into pharmacies.